Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

London pre-open: Stocks seen down ahead of data slew

Published 29/11/2022, 07:30
Updated 29/11/2022, 07:41
London pre-open: Stocks seen down ahead of data slew

Sharecast - The FTSE 100 was called to open 18 points lower at 7,492.

CMC Markets analyst Michael Hewson said: "European markets started the week on the back foot yesterday as sporadic unrest across China sparks a selloff in global equities. The weakness spread across to the US, where we saw similar weakness on reports that Apple’s iPhone sales could be impacted to the tune of 6m handsets from the current disruption.

"With the rest of the world enjoying life, watching the Football World Cup and learning to live with Covid without masks, Chinese authorities are continuing to double down on a strategy that has zero chance of success, and a population increasingly weary after two years of on-off restrictions, and with no endgame in sight."

On the macroeconomic front, net lending, consumer credit and mortgage approvals data for October are due at 0930 GMT.

In corporate news, budget airline easyJet (LON:EZJ) narrowed full-year losses and said it was ramping up preparations for next summer as travellers looked for value for money during the cost-of-living crisis.

The company posted an annual pre-tax loss of £208m compared with a £1bn loss during the Covid pandemic which shut down air travel.

Elsewhere, AstraZeneca (NASDAQ:AZN) said it had agreed to buy biotechnology company Neogene for up to $320m.

Neogene is a clinical-stage company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

"With a shared goal of bringing cell therapies to patients with solid tumours, Neogene's expertise in TCR-T discovery, development and manufacturing will strengthen AstraZeneca's ambition to transform outcomes for patients," it said.

Read more on Sharecast.com

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.